Ra Medical Systems Stock Forecast, Price & News

Ra Medical Systems' stock was trading at $31.4075 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RMED stock has decreased by 76.1% and is now trading at $7.50.
View which stocks have been most impacted by COVID-19.

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ra Medical Systems in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Ra Medical Systems stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMED, but not buy additional shares or sell existing shares.
View analyst ratings for Ra Medical Systems or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Ra Medical Systems a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ra Medical Systems wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

6,978 employees have rated Ra Medical Systems CEO Larry J. Merlo on Glassdoor.com. Larry J. Merlo has an approval rating of 37% among Ra Medical Systems' employees. This puts Larry J. Merlo in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Ra Medical Systems is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Ra Medical Systems.

Ra Medical Systems, Inc. (NYSE:RMED) posted its earnings results on Thursday, November, 12th. The company reported ($3.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($3.00) by $0.25. The company had revenue of $0.91 million for the quarter, compared to analyst estimates of $1.13 million. Ra Medical Systems had a negative return on equity of 120.68% and a negative net margin of 772.04%.
View Ra Medical Systems' earnings history.

Shares of Ra Medical Systems reverse split on Tuesday, November 17th 2020. The 1-25 reverse split was announced on Monday, November 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 16th 2020. An investor that had 100 shares of Ra Medical Systems stock prior to the reverse split would have 4 shares after the split.

3 Wall Street analysts have issued twelve-month price objectives for Ra Medical Systems' shares. Their forecasts range from $7.00 to $50.00. On average, they expect Ra Medical Systems' stock price to reach $31.50 in the next year. This suggests a possible upside of 320.0% from the stock's current price.
View analysts' price targets for Ra Medical Systems or view Wall Street analyst' top-rated stocks.

Ra Medical Systems saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 76,200 shares, an increase of 32.1% from the December 15th total of 57,700 shares. Based on an average daily trading volume, of 255,600 shares, the days-to-cover ratio is currently 0.3 days. Currently, 2.9% of the company's stock are sold short.
View Ra Medical Systems' Short Interest.

Some companies that are related to Ra Medical Systems include SANUWAVE Health (SNWV), Nephros (NEPH), Spectral Medical (EDTXF), Delcath Systems (DCTH), LENSAR (LNSR), AIT Therapeutics (AITB), STRATA Skin Sciences (SSKN), Sensus Healthcare (SRTS), Nephros (NEPHD), Motus GI (MOTS), Sintx Technologies (SINT), Daxor (DXR), Obalon Therapeutics (OBLN), Neovasc (NVCN) and Arch Therapeutics (ARTH).
View all of RMED's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ra Medical Systems investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Cannabics Pharmaceuticals (CNBX), Novan (NOVN), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL) and Zosano Pharma (ZSAN).

(RMED) raised $50 million in an initial public offering on Thursday, September 27th 2018. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and Cantor acted as the underwriters for the IPO and SunTrust Robinson Humphrey, Nomura and Maxim Group were co-managers.

Ra Medical Systems trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMED."

Shares of RMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RMED stock can currently be purchased for approximately $7.50.

Ra Medical Systems has a market capitalization of $21.89 million and generates $7.20 million in revenue each year. The company earns $-56,960,000.00 in net income (profit) each year or ($108.25) on an earnings per share basis. Ra Medical Systems employs 85 workers across the globe.

The official website for Ra Medical Systems is www.ramed.com.

Ra Medical Systems' mailing address is 2070 Las Palmas Drive, Carlsbad CA, 92011. The company can be reached via phone at 760-804-1648 or via email at [email protected]